Epilepsy: Advances in management

European Neurology

Volumn 38, Issue 3, 1997, Pages 198-208

  Blume, Warren T ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Epilepsy; Epilepsy surgery; Mesial temporal epilepsy; New antiepileptic drugs; Recent developments MRI; Temporal lobe epilepsy

Indexed keywords

ANTICONVULSIVE AGENT;

ARTICLE; BRAIN SURGERY; DISEASE MANAGEMENT; DYSPLASIA; EPILEPSY; EPILEPTIC STATE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; TEMPORAL LOBE EPILEPSY;

ANTICONVULSANTS; BRAIN; EPILEPSY; FEMALE; GENETIC MARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT (HEALTH CARE); PREGNANCY; PREGNANCY COMPLICATIONS; QUALITY OF LIFE; STATUS EPILEPTICUS;

EID: 0030983847     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000113374     Document Type: Article

References (110)

1. Zentner J, Hufnagel A, Wolf HK, Ostcrlun B. Behrens E, Campos MG. Solymosi L. Elger CE, Wiestler OD, Schramm J: Surgical treatment of temporal lobe epilepsy: Clinical, radiological, anil hislopalhologital findings in 178 patients. J Neurol Neurosurg Psychiatry 1995:58:666-673.
2. Otsubo H, Hwang PA, Jay V, Becker LE, Hoffman HJ, Gilday D, Blaser S: Focal cortical dysplasia in children with localization-related epilepsy: EEG. MRI, and SPECT findings. Pediatr Neurol 1993;9:101-107.
3. Raymond AA, Fish DR, Sisodiya SM, Alsan-jari N, Stevens JM, Shorvon SD: Abnormalities of gyration, heterotopias, tuberous sclerosis. focal cortical dysplasia, microdysgenesis, dysembryoplastic neuroeptihelial tumour and dysgenesis of the archicortex in epilepsy. Brain 1995;118:629-660.
4. Palmini A, Andermann F, Olivier A, Tampieri D, Robitaille Y, Andermann E, Wright G: Focal neuronal migration disorders and intractable partial epilepsy: A study of 30 patients. Ann Neurol 1991;30:741-749.
5. Jackson GD, Berkovic SF, Tress BM, Kalnins RM, Fabinyi GC, Bladin PF: Hippocampal sclerosis can be reliably detected by magnetic resonance imaging. Neurology 1990;40:1869-1875.
6. Cook MJ, Fish DR, Shorvon SD, Slraughan K, Stevens JM: Hippocampal volumetric and morphometric studies in frontal and temporal lobe epilepsy. Brain 1992:115:1001-1015.
7. Cendes F, Andermann F, Dubeau F, Gloor P, Evans A, Jones-Gotman M, Olivier A. Andermann E, Robitaille Y, Lopes-Cendes I. et al: Early childhood prolonged febrile convulsions, atrophy and sclerosis of mesial structures, and temporal lobe epilepsy: An MRI volumetric study. Neurology 1993;43:1083-1087.
8. Lcncz T, McCarthy G, Bronen RA, Scott I'M, Inserni JA, Sass KJ, Novellv RA, Kim JH, Spencer DD: Quantitative magnetic resonance imaging in temporal lobe epilepsy: relationship to neuropathology and neurophysiological function. Ann Neurol 1992:31:629-637.
9. Lee N, Tien RD, Lewis DV, Friedman AI, Felsberg GJ, Crain B, Hulctte C, Osunu AK. Smith JS. VanLandingham KE. et al: Fast spin-echo. magnetic resonance imaging-measured hippocampal volume: Correlation with neuronal density in anterior temporal lobectomy patients. Epilepsia 1995;36:899-904.
10. Cascino GD, Jack CR Jr, Parisi JE, Marsh WR, Kelly PJ, Sharbrough FW, Hirschom KA, Trenerrv MR: MRI in the prcsurgical evaluation of patients with frontal lobe epilepsy and children with temporal lobe epilepsy: Pathologic correlation and prognostic importance. Epilepsy Res 1992; 11:51-59.
11. Blume WT, Girvin JP, McLachlan RS, Gilmore BE: Effective temporal lobectomy in childhood without invasive EEG. Epilepsia, 1997;38(2): 164-167.
12. Cascino GD, Jack CR Jr, Parisi JE, Sharbrough FW, Schreibcr CP, Kelly PJ, Trencrrv MR: Operative strategy in patients with MR1-idcntified dual pathology and temporal lobe epilepsy. Epilepsy Res 1993, 14:175-182.
13. Raymond AA, Fish DR, Stevens JM, Cook MJ, Sisodiya SM, Shorvon SD: Association of hippocampal sclerosis with cortical dysgenesis in patients with epilepsy. Neurology 1994.44: 1841-1845.
14. Cendes F, Andermann F, Gloor P, Evans A, Jones-Gotman M, Watson C, Mclanson D. Olivier A. Peters T. Lopes-Cendes I, et al: MRI volumetric measurement of amygdala and hippocampus in temporal lobe epilepsy. Neurology 1993;43:719-725.
15. Spencer SS, McCarthy G, Spencer DD: Diagnosis of medial temporal lobe seizure onset: Relative specificity and sensitivity of quantitative MRI. Neurology 1993:43:2117-2124.
16. Jack CR Jr, Mullan BP, Sharbrough FW, Casci-no GD, Hauser MF, Kreckc KN, Luetmer PH, Trcncrrv MR, O’Brien PC, Parisi JE: Intractable nonlesional epilepsy of temporal lobe origin: Lateralization by intcrictal SPECT versus MRI. Neurology 1994;44:829-836.
17. Jackson GD, Connelly A, Duncan JS, Grünewald RA. Gadian DG: Detection of hippocampal pathology in intractable partial epilepsy: Increased sensitivity with quantitative magnetic resonance T2 relaxometry. Neurologv 1993: 43:1793-1799.
18. Pitkanen A, Laakso M, Kalviainen R, Partanen K, Vainio P, Lehtovirta M, Riekkinen P, Soin-iner H: Severity of hippocampal atrophy correlates with the prolongation of MRI T2 relaxation lime in temporal lobe epilepsy but not in Alzheimer’s disease. Neurology 1996:46:1724-1730.
19. Adams C, Hwang PA, Gilday DL. Armstrong DC, Becker LE, Hoffman I1J: Comparison of SPECT, EEG. CT. MRI and pathology in partial epilepsy. Pediatr Neurol 1992:8:97-103.
20. Humbcrstonc MR, Sawlc GV: Functional magnetic resonance imaging in clinical neurology. Eur Neurol 1996;36:l17-124.
21. Hirabavashi S, Binnic CD, Janota I, Polkcy CE: Surgical treatment of epilepsy due to cortical dysplasia: clinical and EEG findings. J Neurol Neurosurg Psychiatry 1993;56:765-770.
22. Gambardclla A, Palmini A, Andermann F, Du-bcau F, Da Costa JC. Quesney LF. Andermann E. Olivier A: Usefulness of focal rhythmic discharges on scalp EEG of patients with focal cortical dysplasia and intractable epilepsy. Elec-trocncephalogr Clin Neurophysiol 1996:98: 243-249.
23. Mathcm GW, Babb TL, Pretorius JK, Melendez M, Levesque MF: The pathophysiologic relationship between lesion pathology, intracranial ictal EEG onsets, and hippocampal neuron losses in temporal lobe epilepsy. Epilepsy Res 1995;21:133-147.
24. Vital A, Marchal C, Loiseau H, Rougier A, Pedcspan JM, Rivel J, Vital C: Glial and ncu-ronoglial malformative lesions associated with medically intractable epilepsy. Acta Ncuropa-thol (Beri) 1994;87:196-201.
25. Jay V, Becker LE, Otsubo H, Hwang PA, Hoff-man HJ, Harwood-Nash D: Pathology of temporal lobectomy for refractory seizures in children. Review of 20 cases including some unique malformative lesions. J Neurosurg 1993;79:53-61.
26. Prayson RA, Reith JD, Najm IM: Mesial temporal sclerosis. A clinicopathologic study of 27 patients, including 5 with coexistent cortical dysplasia. Arch Pathol Lab Med (Chicago) 1996;120:532-536.
27. Palmini A, Andermann F, Olivier A, Tampieri D, Robitaille Y: Focal neuronal migration disorders and intractable partial epilepsy: Results of surgical treatment. Ann Neurol 1991;30: 750-757.
28. Engel J Jr: Update on surgical treatment of the epilepsies: Summary of the Second International Palm Desert Conference on the surgical treatment of the epilepsies (1992). Neurology 1993;43:1612-1617.
29. Jayakar P: Physiological principles of electrical stimulation; in Devinksy O. Beric A. Dogali M (cds): Advances in Neurology, voi 63: Electrical and Magnetic Stimulation of the Brain and Spinal Cord. New York. Raven Press. 1993. pp 17-27.
30. Reeves AG, O’Leary PM: Total corpus calloso-tomy for control of medically intractable epilepsy; in Reeves AG (ed): Epilepsy and the Corpus callosum. New York. Plenum Press, 1985, pp 269-280.
31. Gales JR, Maxwell R, Leppik IE, Fiol ME, Gumnit RJ: Electrocnccphalographic and clinical effects of total corpus callosotomy; in Reeves AG (ed): Epilepsy and the Corpus callosum. New York. Plenum Press. 1985. pp 281-301.
32. Kotagal P, Rothner AD, Ercnbcrg G. Cruse RP. Wyllie E: Complex partial seizures of childhood onset. A five-year follow-up study. Arch Neurol 1987.44:1177-1180.
33. Harbord MG, Manson JI: Temporal lobe epilepsy in childhood: Reappraisal of etiology and outcome. Pediatr Neurol 1987;3:263-268.
34. Hopkins IJ, KJug GL: Temporal lobectomy for the treatment of intractable complex partial seizures of temporal lobe origin in early childhood. Dev Med Child Neurol 1991:33:26-31.
35. Duchowny M, Levin B. Jayakar P. Resnick T, Alvarez L, Morrison G, Dean P: Temporal lobectomy in early childhood. Epilepsia 1992; 33:298-303.
36. So NK: Depth electrode studies in mesial temporal epilepsy; in Luders H (ed): Epilepsy Surgery. New York. Raven Press. 1992. pp 371-384.
37. Parrent AG, Blume WT: Treatment of mesial temporal lobe seizures by stereotaxic amygda-lohippocampolomy (abstract). Epilepsia 1995: 36(suppl 3):S 169.
38. Berkovic SF, McIntosh AM, Kalnins RM, Jackson GD, Fabinvi GC, Brazenor GA. Bla-din PF. Hopper JL: Preopcrativc MR1 predicts outcome of temporal lobectomy: An actuarial analysis. Neurology 1995;45:1358-1363.
39. Jack CR Jr, Sharbrough FW, Cascino GD, Hir-schom KA, O'Brien PC, Marsh WR: Magnetic resonance image-based hippocampal volumetry: Correlation with outcome after temporal lobectomy. Ann Neurol 1992:31:138-146.
40. Kuznieckv R, Burgard S, Faught E, Morawctz R. Bartolueci A: Predictive value of magnetic resonance imaging in temporal lobe epilepsy surgery. Arch Neurol 1993:50:65-69.
41. Garcia PA, Laxer KD, Barbara NM, Dillon WP: Prognostic value of qualitative magnetic resonance imaging hippocampal abnormalities in patients undergoing temporal lobectomy for medically refractory seizures. Epilepsia 1994; 35:520-524.
42. Wiebe S: Quality of life and anliepileptic drugs. The Risk-Bcncfit Ratio of Pharmacological Treatment in Epilepsy. Conference at Chateau Whistler. British Columbia. Canada. Medical Seminar. 1995. pp 1-12.
43. Smith D, Baker G, Davies G. Dewey M, Chadwick DW: Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993; 34:312-322.
44. Rose KJ, Derry PA, Wiebe S, McLachlan RS: Determinants of health-related quality of life after temporal lobe epilepsy surgery. Qual Life Res 1996;5:395-402.
45. Vickrey BG: A procedure for developing a quality-of-life measure for epilepsy surgery patients. Epilepsia 1993:34(suppl 4):S22-S27.
46. Vickrey BG, Hays RD. Engel J Jr, Spritzer K, Rogers WH, Rausch R, Graber J. Brook RH: Outcome assessment for epilepsy surgery: the impact of measuring health-related quality of life. Ann Neurol 1995;37:158-166.
47. Yang T-F, Wong T-T, Kwan S-Y, Chang K-P, Lee Y-C, Hsu T-C: Quality of life and life satisfaction in families after a child has undergone corpus callosotomy. Epilepsia 1996:37:76-80.
48. Celcsia GG: Prognosis in convulsive status epilepticus; in Dclgado-Escucta AV. Wasterlain CG, Treiman DM. Porter RH (eds): Status cpi-lepticus: Mechanisms of Brain Damage and Treatment. Adv Neurol, vol 34. New York. Raven Press, 1993. pp 55-59.
49. DcLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberlhv L, Garnett L. Fort-ncrCA, Ko D: A prospective, population-based epidemiologic study of status epilepticus in Richmond. Virginia. Neurology 1996;46: 1029-1035.
50. Towne AR. Pellock JM. Ko D. DeLorcnzo RJ: Determinants of mortality in status epilepticus. Epilepsia 1994;5:27-36.
51. Goulon M, Levy-Alcover MA, Nouailhat F: Etat de mal épileptique de l’adulte: Etude épi-demiologique et clinique en réanimation. Rev Elcctrocncéphalogr Neurophysiol Clin 1985: 15:277-285.
52. Aicardi J, Chevrie JJ: Consequences of status epilepticus in infants and children: in Dclgado-Escucta AV. Wasterlain CG, Treiman DM. Porter RJ (eds): Adv Neurol, vol 34: Status cpi-leplicus. Mechanisms of Brain Damage and Treatment. New York. Raven Press, 1983, pp 115-125.
53. Maytal J, Shinner S, Moshe SL. Alvarez LA: Low morbidity and mortality of status cpilcpli-cus in children. Pediatrics 1989:83:323-331.
54. Kapur J, Lothman EW, DcLorenzo RJ: Loss of G ABAa receptors during partial status epilepticus. Neurology 1994;44:2407-2408.
55. Kaplan PW: Nonconvulsive status epilepticus in the emergency room. Epilepsia 1996;37: 643-650.
56. Dunne JW, Summers QA, Stewart-Wynne EG: Non-convulsive status epilepticus: A prospective study in an adult general hospital. Q J Med 1987;62(238);117-126.
57. Porter RJ, Penry JK: Petit mal status: in Delgado-Escueta AV. Wasterlain CG, Treiman DM. Porter RJ (eds): Status epilepticus. Adv Neurol, vol 34. New York. Raven Press. 1983. pp 61-67.
58. Krumholz A, Sung GY, Fisher RS, Barry E, Bergey GK, Grattan LM: Complex partial status epilepticus accompanied by serious morbidity and mortality. Neurology 1995:45: 1499-1504.
59. Young GB, Jordan KG, Doig GS: An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring: An investigation of variables associated with mortality. Neurology 1996;47:83-89.
60. Granner MA, Lee SI: Nonconvulsive status epilepticus: EEG analysis in a large series. Epilepsia 1994;35:42-47.
61. Morrell MJ: Epilepsy and pregnancy. Canadian Congress of Neurological Sciences Course: Epilepsy - Current Topics and Relevant Electroencephalography. Victoria, 1995. pp 1-11.
62. Lindhout D, Meinardi H, Meijer JWA, Nau H: Ant ¡epileptic drugs and teratogenesis in two consecutive cohorts: Changes in prescription policy paralleled by changes in patterns of malformations. Neurology 1992;42(suppl 5):94-110.
63. Kaneko S, Otani K, Kondo T, Fukushima Y, Nakamura Y, Ogawa Y, Kan R. Takeda A. Nakane Y. Tcranishi T: Malformation in infants of mothers with epilepsy receiving anti-epileptic drugs. Neurology I992;42(suppl 5): 68-74.
64. Omtzig JGC, Los FJ, Grobec DE, Pijpcrs L, Jahoda MGJ, Brandenburg H, Stewart PA, Gaillard HLJ, Sachs ES, Wladimiroft JW, Lindhout D: The risk of spina bifida apcrta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992:42(suppl 5): 119-125.
65. Rosa FW: Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-677.
66. Koch S, Locschc G, Jager-Roman E, Jakob S: Major and minor birth malformations and an-ticpileptie drugs. Neurology 1992:42(suppl 5): 83-88.
67. Ogawa Y, Kaneko S, Otani K, Fukushima Y: Scrum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991:8:75-78.
68. Mulinare J, Cordero JF, Erickson JD, Berry RJ: Pcriconceplional use of multivitamins and the occurrence of neural tube defects. JAMA 1988;260:3141-3145.
69. Czcizcl AE, Dudas I: Prevention of the first occurrence of neural tube defects by pericon-ccptional vitamin supplementation. N Engl J Med 1992;327:1832-1835.
70. Delgado-Escueta AV, Janz D: Consensus guidelines: Preconception counseling, management. and care of the pregnant woman with epilepsy. Neurology 1992;42(suppl 5): 149-160.
71. Finnell RH, Nau H, Yerby MS: General principles. Teratogenicity of antiepilcptics drugs: in Levy RH, Mattson RH, Meldrum BS (eds): Antiepileptic Drugs, ed 4. New York, Raven Press, 1995, pp 209-230.
72. Delgado-Escueta AV, Greenberg D, Weiss-becker K, Liu A, Treiman L, Sparkes R. Park MS. Barbctti A, Tcrasaki PJ: Gene mapping in the idiopathic generalized epilepsies. Epilepsia 1990;31(suppl 3):S19-S29.
73. Dumer M, Sander T. Greenberg DA, Johnson K, Beck-Mannagetta G, Janz D: Localization of idiopathic generalized epilepsy on chromosome 6p in families of juvenile myoclonic epilepsy patients. Neurology 1991;41:1651-1655.
74. Whilehouse WP, Rees M, Curtis D, Sundqvist A, Parker K, Chung E, Baralle D, Gardiner RM: Linkage analysis of idiopathic generalized epilepsy (1GE) and marker loci on chromosome 6p in families of patients with juvenile myoclonic epilepsy: No evidence for an epilepsy locus in the HLA region. Am J Hum Genet 1993:53:652-662.
75. Janz D, Beck-Mannagetta G, Sander T: Do idiopathic generalized epilepsies share a common susceptibility gene? Neurology 1992: 42(supp1 5):48-55.
76. Greenberg DA, Delgado Escueta AV, Maldonado HM, Widelitz H: Segregation analysis of juvenile myoclonic epilepsy. Genet Epidemiol 1988;5:81-94.
77. Lehesjoki A-E, Koskiniemi M, Sistonen P, Miao J, Hastbacka J. Norio R, de la Chapelle A: Localization of a gene for progressive myoclonus epilepsy to chromosome 21q22. Proc Natl Acad Sei USA 1991:88:3696-3699.
78. Lehesjoki A-E, Eldridge R, Eldridge J, Wilder BJ, dc la Chapelle A: Progressive myoclonus epilepsy of Unvcrrichl-Lundborg type: A clinical and molecular genetic study of a family from the United States with four affected sibs. Neurology 1993;43:2384-2386.
79. Shoffner JM, Lott MT, Lezza AMS, Scibcl P, Ballinger SW, Wallace DC: Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA Lys mutation. Cell 1990:61:931-937.
80. Leppert M, Anderson VE, Quattlcbaum T, Stauffer D, O'Connell P, Nakamura Y, Laloucl JM. White R: Benign familial neonatal convulsions linked to genetic markers on chromosome 20. Nature 1989;337:647-648.
81. Ryan SG, Wiznilzer M, Hollman C, Torres CM, Szckcresova M, Schneider S: Benign familial neonatal convulsions: Evidence for clinical and genetic heterogeneity. Ann Neurol 1991:29:469-473.
82. Lewis TB, Leach RJ, Ward K, O'Connell P, Ryan SG: Genetic heterogeneity in benign familial neonatal convulsions: Identification of a new locus on chromsomc 8q. Am J Hum Genet 1993:53:670-675.
83. Berkovic SF, Rcutens DC, Andermann E, Andermann F: The epilepsies: specific syndromes or a neurobiological continuum? in Wolf P (ed): Epileptic Seizures and Syndromes. London. Libbey, 1994, pp 25-37.
84. Andermann E: Multifactorial inheritance of generalized and focal epilepsy; in Anderson VE. Hauser WA, Penry JK. Sing CF (eds): Genetic Basis of the Epilepsies. New York. Raven Press. 1982. pp 129-145.
85. Noebels JL: Targeting epilepsy genes. Neuron 1996:16:241-244.
86. Rimoin DL, Metrakos JD: The genetics of convulsive disorders in the families of hcmiplcgics; in Proc 2nd Int Congr Hum Genet 1964, pp 1655-1658.
87. Ryan SG: Partial epilepsy: Chinks in the armour. Nature Genet 1996;10:4-6.
88. Ottman R, Annegers JF, Risch N, Hauser WA, Susser M: Relations of genetic and environmental factors in the etiology of epilepsy. Ann Neurol 1996;39:442-449.
89. Noebels JL: Mutational analysis of spike-wave epilepsy phenotypes. Epilepsy Res Suppl 1991; 4:201-212.
90. Phillips HA, Schcffcr IE, Berkovic SF, Hollway GE. Sutherland GR, Mulley JC: Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q 13.2 Nature Genet 1995:10:117-118.
91. Steinlein OK, Mulley JC, Propping P, Wallace RH. Phillips HA, Sutherland GR. Schcffcr IE. Berkovic SF: A missensc mutation in the neuronal nicotinic acetylcholine receptor a4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nature Genet 1995:11:201-203.
92. Lang DG, Wang CM: Lamotrigine and phcny-toin interactions on ionic channels present in N4TG1 and GI13 clonal cells. Soc Neurosci Abstr 1991:17:1256.
93. Lees G, Leach MJ: Studies on the mechanism of action of the novel anticonvulsant lantolri-ginc (Lamictal) using primary neuroglia! cultures from rat cortex. Brain Res 1993:612:190-199.
94. Leach JP, Brodic MJ: Lamotrigine. Clinical use; in Levy RH. Mattson RH. Meldrum BS (eds): Antiepilcptic Drugs, ed 4. New York. Raven Press, 1995. pp 889-895.
95. Jung MJ, Palfreyman MG: Vigabatrin. Mechanisms of action: in Levy RH. Mattson RH. Meldrum BS (eds): Antiepilcptic Drugs, cd 4. New York. Raven Press. 1995. pp 903-913.
96. Kalviainen R, Mcrvaala E, Sivenius J, Rick-kincn PJ Sr: Vigabatrin. Clinical use; in Levy RH. Mattson RH. Meldrum BS (eds): Antiepileptic Drugs, ed 4. New York, Raven Press. 1995, pp 925-930.
97. Taylor CP: Gabapentin. Mechanisms of action; in Levy RH. Mattson RH. Meldrum BS (eds): Antiepileptic Drugs, ed 4. New York. Raven Press, 1995, pp 829-841.
98. Chadwick D: Gabapentin. Clinical use: in Levy RH. Mattson RH. Meldrum BS (eds). Antiepilcptic Drugs, ed 4. New York, Raven Press. 1995. pp 851-856.
99. Cramer JA, Smith DB, Mattson RH, Delgado-Escueta AV, Collins JF: A method of quantification for the evaluation of anticpi-leptic drug therapy. Neurology 1983:33(suppl I):26-37.
100. Walker MC, Sander JWAS: The impact of new antiepilcptic drugs on the prognosis of epilepsy. Seizure freedom should be the ultimate goal. Neurology 1996:46:912-914.
101. White HS, Woodhead JH, Franklin MR, Swinvard EA, Wolf HH: General principles. Experimental selection, quantification, and evaluation of antiepilcptic drugs; in LevyRH. Mattson RH. Meldrum BS (eds): Antiepileptic Drugs, ed 4. New York, Raven Press. 1995, pp 99-110.
102. Dakin KA, Weaver DF: Rational design of anticonvulsants: A quantum pharmacologic study of the ion channel - modulating FMRF amide tetrapcptidc as an endogenous anticonvulsant. Epilepsia 1995;36:494-507.
103. Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J: Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991;6:52-59.
104. Bcn-Menachem E: Vigabatrin. Chemistry, absorption, distribution, and elimination; in Levy RH, Mattson RH. Meldrum BS (eds): Anticpileptic Drugs, ed 4. New York. Raven Press. 1995. pp 915-923.
105. Fisher RS, Kerrigan JF III: Vigabatrin. Toxicity; in Levy RH. Mattson RH. Meldrum BS (eds): Antiepilcptic Drugs, ed 4. New York. Raven Press, 1995. pp 931-939.
106. Yuen AWC: Lamotrigine. Interactions with other drugs; in Levy RH. Mattson RH. Mcl-drum BS (eds): Antiepilcptic Drugs, cd 4. New York, Raven Press. 1995. pp 883-887.
107. Richens A: Lamotrigine. Toxicity: in Levy RH. Mattson RH. Meldrum BS (eds): Antiepileptic Drugs, ed 4. New York. Raven Press, 1995, pp 897-902.
108. McLean MJ: Gabapentin.Chemistry, absorption, distribution and excretion: in Levy RH, Mattson RH. Meldrum BS (eds): Antiepilcptic Drugs, ed 4. New York. Raven Press. 1995, pp 843-849.
109. Ramsay RE: Gabapentin. Toxicity: in Levy RH, Mattson RH. Meldrum BS (eds). Anti-epileptic Drugs, ed 4. New York, Raven Press. 1995. pp 857-860.
110. Blume WT: Temporal lobe epilepsy surgery in childhood: rationale for greater use. Can J Neurol Sci 1997:24:95-98.